Background
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide [
1]. Recently, the development of surgical techniques and target therapies has led to a significant improvement in survival. Currently, early gastric carcinoma (EGC) has a 5-year survival rate of over 90% [
2]. However, for cases of advanced GC (AGC), the survival rate is still around 40% [
3]. Thus, a new biomarker for AGC is urgently needed.
The Wnt signaling cascade governs cell proliferation, cell polarity, and cell fate during embryonic development and homeostasis in human tissues [
4]. Solid tumors frequently exhibit dysregulated Wnt signaling pathways, and this dysregulation is linked to enhanced malignant potential [
5]. In GC, activation of the Wnt/ß-catenin pathway is found in approximately 30% to 50% of tumors [
6,
7]. The first step in activation is the binding of the Wnt ligand to the seven-pass transmembrane Frizzled receptor (FZ), low-density lipoprotein receptor-related protein 6 (LRP 6), and LRP 5. The Wnt-FZ-LRP5/6 complex disrupts Axin-mediated ß-catenin phosphorylation, resulting in ß-catenin stabilization. Accumulation of ß-catenin in the cytoplasm results in its transport to the nucleus, where ß-catenin forms complexes with T-cell factor (TCF)/lymphoid enhancer factor and activates Wnt-targeted gene expression (cyclin D1,
c-MYC, axin-2) [
5,
8]. Wnt signaling can be repressed by six Wnt antagonist families, including Dickkopf (DKK) proteins, secreted Frizzled-related proteins, WNT-inhibitory factor 1, Wise/SOST, Cerberus, and insulin-like growth-factor binding protein 4 [
9]. DKK1, the most well-known Wnt antagonist, is a 35 kDa protein that contains a secreted signal peptide sequence [
10]. Antagonism of the Wnt pathway via antagonists such as DKK1 is accomplished through binding to LRP 5/6 [
11,
12]. Despite being a negative regulator of Wnt signaling, the prognostic role of DKK1 is not well understood. Results from previous studies on DKK1 in diverse tumors have demonstrated conflicting results; some have reported that DKK1 acts as a tumor suppressor, while others have shown that it acts as an oncogene [
13]. Lee et al. and Gao et al. reported that overexpression of DKK1 protein and mRNA in tissue and increased levels of DKK1 in serum were significantly associated with unfavorable prognosis in patients with GC [
14,
15]. In contrast, other recent studies showed low DKK1 expression in GC samples, and that restoration of DKK1 in tumor cells inhibited tumor cell growth and invasion [
16,
17]. However, the prognostic value of DKK1 in GC is not clearly determined. Furthermore, although DKK1 interacts with ß-catenin, the association between DKK1 and abnormal ß-catenin expression has not been well studied. Therefore, we aimed to confirm the role of DKK1 as a prognostic factor in AGC and to determine the association between DKK1 and ß-catenin in a sizable AGC cohort using immunohistochemistry.
Discussion
In this study, high DKK1 expression was significantly associated with high N stage, and patients with high DKK1 expression demonstrated shorter OS and DFS. High DKK1 expression was also correlated with β-catenin positivity. On multivariate analysis, high DKK1 expression and β-catenin positivity were found to be independent adverse prognostic factors for both OS and DFS. Interestingly, patients with high DKK1 expression and concomitant β-catenin negativity also had shorter OS and DFS. Thus, the prognostic value of DKK1 in GC patients may be independent of β-catenin expression.
Various tumors have shown conflicting results regarding the role of DKK1 as a tumor suppressor or oncogene. DKK1 is a secreted protein that plays a crucial role as a negative regulator of the Wnt signaling pathway, and downregulation of DKK1 in colon cancer, breast cancer, hepatocellular carcinoma, and renal cell carcinoma suggests that DKK1 is an antagonist of the Wnt signaling pathway. However, overexpression of DKK1 has been observed in various malignant tumors and is also correlated with adverse prognosis in patients with multiple myeloma, hepatoblastoma, Wilm’s tumor, lung cancer, and breast cancer [
19‐
22].
Although DKK1 has been investigated extensively in various tumors, including GC, no previous studies have evaluated the association between DKK1 and β-catenin expression in AGC. Previous studies have shown that overexpression of DKK1 is related to adverse prognosis in GC [
14,
15]. This is consistent with the results we obtained in the high DKK1 expression group, which showed that regardless of β-catenin expression, high DKK1 expression is related to unfavorable prognosis. In previous studies, high DKK1 expression was found to be associated with intestinal GC, advanced T stage, vascular and lymphatic invasion, and distant metastasis. However, we only found a significant association between N stage and high DKK1 expression. This discrepancy might stem from different cut-off values and patient cohorts among studies. Our cut-off value was meticulously determined and optimized for patient survival using maximally selected rank statistics. Therefore, we suggest that our cut-off value better reflects the prognostic role of DKK1 in GC, independently of other adverse clinicopathologic parameters. Previous clinical studies of DKK1 expression in GC included both early GC and AGC, with a number of distant metastasis cases [
14,
15]. Survival of early gastric carcinoma patients is over 90%, but survival of patients with both GC and distant metastasis is less than 10% [
23]. Therefore, clarification of the prognostic impact of DKK1 could be confounded by the heterogenous patient cohorts used in previous studies.
Wan et al. reported that adenovirus-mediated DKK1 overexpression in CD44
+ GC cells inhibits tumorigenicity through attenuating Wnt signaling [
16]. The results indicate that DKK1 plays a tumor suppressor role in GC stem cells. However, the authors only evaluated the CD44
+ GC cell line. Although cancer stem cells play a crucial role in GC, they are not entirely representative of GC. Given that the tumor cell, tumor environment, and cell–cell interactions all contribute to GC, studies using limited gastric cancer cell line was further validated.
Activation of Wnt/β-catenin is found in 30% to 50% of GC tissue samples and cell lines [
6,
24]. Furthermore, recent studies that used high-throughput sequencing methods showed that
CTNNB1, which encodes β-catenin, is a driver gene for GC [
25‐
27]. However,
CTNNB1 gene mutations were only detected in 4% to 9% of sporadic GC tumors [
28,
29]. These findings suggest that aberrant activation of Wnt signaling pathway is modulated mainly by Wnt ligands and negative regulators, not through mutation of the
CTTNB1 gene. In this study, high DKK1 expression was significantly related to positive β-catenin expression in AGC samples. Given that DKK1 inhibits β-catenin, this finding may seem contradictory. However, several tumor studies revealed that high DKK1 expression is correlated with activation of the Wnt/β-catenin pathway in both hepatocellular carcinoma and hilar cholangiocarcinoma [
20,
30]. These findings could be explained by a disruption in the negative feedback loop between DKK1 and the Wnt/β-catenin pathway, which could result from a high level of secreted DKK1 [
31]. In addition, DKK1 is also a downstream target gene of β-catenin/TCF, which is a direct target of activated β-catenin [
32].
The OS and DFS of patients with high DKK1 and negative β-catenin expression were not different from those with high DKK1 and positive β-catenin expression. These results suggest that the effect of high DKK1 expression in AGC could be an independent of β-catenin status. Conversely, high DKK1 expression, which does not affect canonical Wnt/β-catenin signaling, is still a prognostic factor for patients with AGC.
Our results suggest that high DKK1 expression affects prognosis regardless of β-catenin activation. Several previous studies showed that DKK1 promotes malignancy via non-canonical Wnt pathway mechanisms. In hepatocellular carcinoma, high DKK1 mRNA and protein expression was correlated with poor OS and DFS. In addition, a positive relationship among DKK1 expression, JNK phosphorylation, and RhoA levels was identified [
33]. These results indicate that the malignant potential can be increased by the interaction between DKK1 and the non-canonical Wnt pathway, which consists of the Wnt/Ca
2+ and Wnt/PCP pathways and does not involve activation of β-catenin [
34]. Moreover, Kimura et al. reported that cytoskeleton-associated protein 4, a receptor for DKK1, mediates DKK1 signaling to promote cancer cell proliferation via the PI3K/AKT pathway and was associated with an unfavorable prognosis in pancreatic and lung cancer patients [
35]. Together, these results suggest that high DKK1 expression acts through β-catenin-independent mechanisms to increase the malignant potential and decrease survival in patients with AGC.
Unfortunately, molecular targeting therapies for AGC are limited to trastuzumab and ramucirumab [
36,
37]. Due to the shortage of promising target agents for GC, new targets molecules with potential agents are urgently needed. The efficacy of an anti-DKK1 antibody has been investigated in multiple myeloma and prostate cancers that were associated with bone resorption [
38,
39]. However, further preclinical studies to determine the effectiveness of anti-DKK1 antibody in GC are required.
Soon Auck Hong: Clinical Assistant Professor, Department of Pathology, Soonchunhyang Cheonan University Hospital, Cheonan, Republic of Korea.
Soo Hyun Yoo: Pathologist, Medical Clinic Laboratory Department of U2Bio Co. Ltd., Seoul, Republic of Korea.
Han Hong Lee: Associate Professor, Department of General Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Der Sheng Sun: Clinical Associate Professor, Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hye Sung Won: Associate Professor, Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Okran Kim: Researcher, Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yoon Ho Ko: Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea and Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.